Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

被引：0

作者：

Nicola Silvestris

Gennaro Ciliberto

Paolo De Paoli

Giovanni Apolone

Maria Luisa Lavitrano

Marco A. Pierotti

Giorgio Stanta

机构：

[1] Medical Oncology Unit and Scientific Directorate,

[2] Cancer Institute “Giovanni Paolo II”,undefined

[3] Scientific Directorate,undefined

[4] IRCCS National Cancer Institute “Regina Elena”,undefined

[5] Scientific Directorate,undefined

[6] IRCCS “Centro di Riferimento Oncologico”,undefined

[7] Scientific Directorate,undefined

[8] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined

[9] BBMRI.it and Department of Medicine and Surgery University Milano-Bicocca,undefined

[10] Senior Group Leader Foundation Institute FIRC Molecular Oncology (IFOM) Milan,undefined

[11] Department of Medical Sciences of the University of Trieste,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 36卷

关键词：

Dynamic; Fluid; Personalized medicine; Target therapy; Clinical trials; N-of-1 trials;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term “Liquid dynamic medicine” in the place of “Personalized or Precision medicine”. Clinical validation of the “Liquid dynamic medicine” approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.

引用

共 50 条

[21] Randomized n-of-1 Trials: Quality Improvement, Research, or Both?
Samuel, Joyce P.
Burgart, Alyssa
Wootton, Susan H.
Magnus, David
Lantos, John D.
Tyson, Jon E.
PEDIATRICS, 2016, 138 (02)
[22] n-of-1 trials and their combination:: Suitable approaches for CAM research?
Hart, A
Sutton, CJ
COMPLEMENTARY THERAPIES IN MEDICINE, 2003, 11 (04) : 213 - 214
[23] Dialysis Research and N-of-1 Trials: Made for Each Other?
Zucker, Deborah R.
Deo, Aneet
Schmid, Christopher H.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : 635 - 638
[24] Time for N-of-1 trials in clinical decision-making
Husain, Masud
BRAIN, 2021, 144 : 1031 - 1032
[25] Using n-of-1 trials as a clinical tool to improve prescribing
Nikles, CJ
Clavarino, AM
Del Mar, CB
BRITISH JOURNAL OF GENERAL PRACTICE, 2005, 55 (512): : 175 - 180
[26] N-of-1 Clinical Trials: Removing the Hay to Find the Needle
Strathmann, Frederick G.
CLINICAL CHEMISTRY, 2015, 61 (12) : 1550 - 1551
[27] Single-Case Experimental Designs and N-of-1 Trials-An Alternative to Randomized Clinical Trials for Clinical Research in Otorhinolaryngology
Taoui, Soumia
Lepage, Benoit
Marx, Mathieu
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2023, 149 (09) : 767 - 768
[28] Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials
Zheng, Ju-Sheng
Ordovas, Jose M.
JOURNAL OF DIABETES, 2021, 13 (12) : 1059 - 1061
[29] Perspective: Application of N-of-1 Methods in Personalized Nutrition Research
Potter, Tilly
Vieira, Rute
de Roos, Baukje
ADVANCES IN NUTRITION, 2021, 12 (03) : 579 - 589
[30] The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, Elizabeth O.
Patay, Bradley
Diamant, Joel
Issell, Brian
Topol, Eric J.
Schork, Nicholas J.
PERSONALIZED MEDICINE, 2011, 8 (02) : 161 - 173

← 1 2 3 4 5 →